RxDoctor Payments Data

Miranda McGhee, MD

Infectious Disease · Oklahoma City, OKNPI 1538547336

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Gilead at 30.7% of the total.

$1,655in general payments, 2019–2025

Across 73 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$508
  • Viiv Healthcare Company$259
  • Insmed, Inc.$217
  • Shionogi Inc$178
  • Amgen$115
  • GSK$108
  • plus $270 from 7 others

What the payments were for

  • Food & beverage$1,655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,655 in reported general payments places this provider in the 70th percentile of 51 infectious disease providers in Oklahoma.

See all infectious disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$180,274
Medicare patients
449
Services billed
28,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala116$462,710
Daptomycin78$48,884
Itraconazole23$15,122
CeftriaxoneCeftriaxone Sodium95$10,557
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam30$8,735
ErtapenemErtapenem Sodium16$6,222
Ceftazidime33$4,839
Vancomycin Hcl29$3,635
Cefazolin Sodium45$2,783
Doxycycline Hyclate42$1,724
Azithromycin32$1,605
Ethambutol Hcl24$1,238
Cephalexin31$1,035
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$859
Fluconazole32$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$508$462,710116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 51 infectious disease providers in Oklahoma.

Other infectious disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →